Provided are treprostinil derivatives with a reduced ability to form undesired impurities in a pharmaceutical formulation, such as a dry powder formulation, further containing a carboxyl group containing inactive ingredient, such as fumaryl dikctopiperazinc.
12 - Land, air and water vehicles; parts of land vehicles
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Aircraft; Electrically powered aircraft; Vertical take-off and landing (VTOL) aircraft (1) Research and development in the field of electrically powered aircraft
12 - Land, air and water vehicles; parts of land vehicles
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Aircraft; Electrically powered aircraft; Vertical take-off and landing (VTOL) aircraft (1) Research and development in the field of electrically powered aircraft
12 - Land, air and water vehicles; parts of land vehicles
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Aircraft; Electrically powered aircraft; Vertical take-off and landing (VTOL) aircraft (1) Research and development in the field of electrically powered aircraft
Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.
A method of producing an oral osmotic pharmaceutical delivery system by using a statistical modeling. The method includes determining a desired average dissolution profile for the active pharmaceutical ingredient; and controlling tablet strength, acetyl content of the cellulose acetate and weight gain of the semi-permeable membrane of the tablet to produce a pharmaceutical batch of tablets having the desired dissolution profile.
12 - Land, air and water vehicles; parts of land vehicles
42 - Scientific, technological and industrial services, research and design
Goods & Services
Aircraft; Electrically powered aircraft; Vertical take-off and landing (VTOL) aircraft Research and development in the field of electrically powered aircraft
12 - Land, air and water vehicles; parts of land vehicles
42 - Scientific, technological and industrial services, research and design
Goods & Services
Aircraft; Electrically powered aircraft; Vertical take-off and landing (VTOL) aircraft Research and development of technology in the field of electrically powered aircraft
9.
A METHOD OF PRODUCING AN ORAL OSMOTIC PHARMACEUTICAL DELIVERY SYSTEM AND A PHARMACEUTICAL BATCH PRODUCED USING THE SAME
A method of producing an oral osmotic pharmaceutical delivery system by using a statistical modeling. The method includes determining a desired average dissolution profile for the active pharmaceutical ingredient; and controlling tablet strength, acetyl content of the cellulose acetate and weight gain of the semi-permeable membrane of the tablet to produce a pharmaceutical batch of tablets having the desired dissolution profile.
Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound.
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same. A preferred polymer has a repeating unit of the following structure:
Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same. A preferred polymer has a repeating unit of the following structure:
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 31/558 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
C07C 67/08 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
13.
AUTOMATED BIOREACTOR SYSTEM, SYSTEM FOR AUTOMATICALLY IMPLEMENTING PROTOCOL FOR DECELLULARIZING ORGAN, AND WASTE DECONTAMINATION SYSTEM
An automated bioreactor system for decellularizing an organ includes a main chamber for containing the organ. The system further includes a reagent chamber containing a liquid phase reagent. A reagent conduit delivers the liquid phase reagent to the main chamber, and a perfusion conduit delivers the reagent from the reagent outlet in the main chamber into the organ. A perfusion pump drives the flow of the reagent. A perfusion pressure sensor detects a pressure of the flowing reagent. A control system controls the perfusion pump to drive the flow of the reagent based on a received input representative of a desired pressure and a received input of the detected pressure. The control system may automatically perform all of the steps of a decellularization protocol based on sensor input. An automated waste decontamination system may also be provided.
Provided are novel treprostinil derivatives, including treprostinil prodrugs and treprostinil analogs, as well as methods of making and using these compounds.
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
C07C 69/712 - Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
Goods & Services
Patient support services on behalf of pharmaceutical manufacturers for the benefit of patients of pharmaceutical manufacturers including enrolling patients of pharmaceutical manufacturers in support programs that enables the patients to view, track and manage the support program wherein the patient support program provides pharmaceutical product and medication education, medication adherence support, visibility into medication delivery and case status, clinical support services, access to financial assistance programs, payer coverage status updates, patient engagement services and reminders and notifications Providing information to patients and caregivers on available financial support for pharmaceutical treatments Educational services, namely, online and telephone coaching for patients and caregivers about disease management and treatment information to improve understanding by patients and caregivers about pharmaceutical treatments and administration
Provided are novel methods of treating pulmonary hypertension comprising monitoring mean pulmonary arterial pressure in a subject, administering a first therapeutically effective amount of a pulmonary vasodilator when mean pulmonary pressure exceeds a threshold value in the subject, and administering an increasing dose of the pulmonary vasodilator until mean pulmonary arterial pressure is reduced.
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
Provided are novel treprostinil derivatives, including treprostinil prodrugs and treprostinil analogs, as well as methods of making and using these compounds.
C07C 69/63 - Halogen-containing esters of saturated acids
C07C 69/675 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
Provided are novel methods of treating pulmonary hypertension comprising monitoring mean pulmonary arterial pressure in a subject, administering a first therapeutically effective amount of a pulmonary vasodilator when mean pulmonary pressure exceeds a threshold value in the subject, and administering an increasing dose of the pulmonary vasodilator until mean pulmonary arterial pressure is reduced.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
The present disclosure provides for treating pulmonary hypertension by administering to a subject suffering from pulmonary hypertension a therapeutically effective amount of a non-oral therapeutic agent for treating pulmonary hypertension followed by an orally administered form of a therapeutic agent for treating pulmonary hypertension, wherein the amount of non-oral therapeutic agent is sufficient to allow for an increased amount of the orally administered therapeutic agent to thereafter be administered compared to a subject who is not previously treated with the non-oral therapeutic agent.
The present disclosure provides for treating pulmonary hypertension by administering to a subject suffering from pulmonary hypertension a therapeutically effective amount of a non-oral therapeutic agent for treating pulmonary hypertension followed by an orally administered form of a therapeutic agent for treating pulmonary hypertension, wherein the amount of non-oral therapeutic agent is sufficient to allow for an increased amount of the orally administered therapeutic agent to thereafter be administered compared to a subject who is not previously treated with the non-oral therapeutic agent.
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/6615 - Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
26.
TREATMENT OF PULMONARY ARTERIAL HYPERTENSION WITH PROSTACYCLIN-TREATED ENDOTHELIAL PROGENITOR CELLS
The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
A61K 35/02 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
27.
TREATMENT OF VASCULOPATHY WITH PROSTACYCLIN AND MESENCHYMAL STEM CELLS
Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Described herein are ralinepag prodrugs, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound, such as but not limited to pulmonary hypertension (PH) diseases.
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
C07D 211/32 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
C07D 295/195 - Radicals derived from nitrogen analogues of carboxylic acids
31.
Crystalline prostacyclin (IP) receptor agonist and uses thereof
Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound.
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
Nebulizers and inhalers for administering medication in the form of a mist inhaled into the lungs, for treatment of pulmonary hypertension and heart and lung diseases
33.
PROCESS TO PREPARE TREPROSTINIL, THE ACTIVE INGREDIENT IN REMODULIN®
This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
C07C 51/08 - Preparation of carboxylic acids or their salts, halides, or anhydrides from nitriles
C07C 51/41 - Preparation of salts of carboxylic acids by conversion of the acids or their salts into salts with the same carboxylic acid part
C07C 213/08 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
C07C 59/72 - Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
C07C 405/00 - Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins
C07C 253/00 - Preparation of carboxylic acid nitriles
refrigerated transport containers for use in the cold storage of organs for transplant nonmetal and non-paper containers for storage and transport of organs for transplant
Described herein are ralinepag prodrugs, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound, such as but not limited to pulmonary hypertension (PH) diseases.
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
A61K 31/325 - Carbamic acidsThiocarbamic acidsAnhydrides or salts thereof
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound.
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/265 - Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
40.
METHODS AND COMPOSITIONS FOR IMPROVING ENDOTHELIAL CELL BARRIER
Described herein are methods and compositions for use in improving a vascular barrier of endothelial cells. The methods may include the use of barrier agonist compounds and improved techniques for culturing endothelial cells. The improved methods and compositions for culturing endothelial cells may include at least one or more of the following: an adenylyl cyclase activator; an activator of Sphingosine- 1 -phosphate (SIP) receptor internalization; a direct or indirect inducer of tight junction protein expression, and a direct or indirect inducer of adherens junction protein expression.
Described herein are methods and compositions for use in improving a vascular barrier of endothelial cells. The methods may include the use of barrier agonist compounds and improved techniques for culturing endothelial cells. The improved methods and compositions for culturing endothelial cells may include at least one or more of the following: an adenylyl cyclase activator; an activator of Sphingosine- 1 -phosphate (SIP) receptor internalization; a direct or indirect inducer of tight junction protein expression, and a direct or indirect inducer of adherens junction protein expression.
Described herein are methods and compositions for use in improving a vascular barrier of endothelial cells. The methods may include the use of barrier agonist compounds and improved techniques for culturing endothelial cells. The improved methods and compositions for culturing endothelial cells may include at least one or more of the following: an adenylyl cyclase activator; an activator of Sphingosine-1-phosphate (S1P) receptor internalization; a direct or indirect inducer of tight junction protein expression, and a direct or indirect inducer of adherens junction protein expression.
C07D 307/93 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
44.
ENHANCEMENT OF MSC IMMUNOMODULATORY PROPERTIES BY TREPROSTINIL
Provided are methods for treating or preventing vasculopathy comprising administering to a subject in need thereof, ac composition comprising a mesenchymal stem cell (MSC), or a part of a culture medium that has been in contact with the MSC and comprises one or more components of the MSC, or an exosome derived from the MSC. Pharmaceutical compositions suitable for such treatment is also provided.
Systems and methods are provided for evaluating a tissue that utilize a resistance to represent pressure of a fluid or gas passing through the tissue and a capacitance to represent compliance of the tissue.
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
A61B 5/021 - Measuring pressure in heart or blood vessels
Systems and methods are provided for evaluating a tissue that utilize a resistance to represent pressure of a fluid or gas passing through the tissue and a capacitance to represent compliance of the tissue.
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
A method is disclosed for separating cells from a lung. Mechanical pressure can be used in one stage of the process to increase the yield of separated cells, including alveolar type II cells.
Systems and methods are provided for evaluating a tissue that utilize a resistance to represent pressure of a fluid or gas passing through the tissue and a capacitance to represent compliance of the tissue.
A method is disclosed for separating cells from a lung. Mechanical pressure can be used in one stage of the process to increase the yield of separated cells, including alveolar type II cells.
Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
A method is disclosed for separating cells from a lung. Mechanical pressure can be used in one stage of the process to increase the yield of separated cells, including alveolar type II cells.
A system comprises a fluid supply, a pressure regulator, a pressure valve, and a vent assembly. The fluid supply stores a volume of a fluid and is fluidly coupled to an outlet tube. The outlet tube is configured to be fluidly coupled to at least a portion of an organ environment. The organ environment configured to hold an organ. The pressure regulator is fluidly coupled to the outlet tube and is configured to maintain a fluid pressure of the fluid being supplied to the organ environment from the outlet tube. The fluid being supplied is at a pressure range above ambient to maintain the organ in an inflated position. The pressure valve is fluidly coupled to the outlet tube and inhibits increase of the fluid pressure above a threshold. The vent assembly removes excess fluid from the organ environment and includes a vent tube disposed within the organ environment and a vent valve disposed outside of the organ environment.
A system (400) comprises a fluid supply (414), a pressure regulator (418), a pressure valve (420), and a vent assembly (422). The fluid supply is fluidly coupled to an outlet tube (416), which is configured to be fluidly coupled to at least a portion of an organ environment (404). The pressure regulator is configured to provide the fluid to an organ (402) in the organ environment via the outlet tube. The fluid being supplied is at a pressure range above ambient to maintain the organ in an inflated position. The pressure valve is fluidly coupled to the outlet tube and inhibits increase of the fluid pressure above a threshold. The vent assembly removes excess fluid from the organ environment and includes a vent tube disposed within the organ environment and a vent valve disposed outside of the organ environment. In another system a fluid condenser may be provided, wherein the pressure controller provides a fluid (e.g., ambient air) through a fluid valve and to the fluid condenser, which condenses the fluid (e.g., removing gases such that the supplied fluid is primarily oxygen).
A system (400) comprises a fluid supply (414), a pressure regulator (418), a pressure valve (420), and a vent assembly (422). The fluid supply is fluidly coupled to an outlet tube (416), which is configured to be fluidly coupled to at least a portion of an organ environment (404). The pressure regulator is configured to provide the fluid to an organ (402) in the organ environment via the outlet tube. The fluid being supplied is at a pressure range above ambient to maintain the organ in an inflated position. The pressure valve is fluidly coupled to the outlet tube and inhibits increase of the fluid pressure above a threshold. The vent assembly removes excess fluid from the organ environment and includes a vent tube disposed within the organ environment and a vent valve disposed outside of the organ environment. In another system a fluid condenser may be provided, wherein the pressure controller provides a fluid (e.g., ambient air) through a fluid valve and to the fluid condenser, which condenses the fluid (e.g., removing gases such that the supplied fluid is primarily oxygen).
Described herein are noninvasive electrical stimulation devices, systems and methods for stimulation of the Vagus nerve through its auricular branch to provide beneficial physiological responses in subjects, including alleviation, mitigation or elimination of symptoms of various disorders, including metabolic and inflammatory disorders.
Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/6615 - Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
60.
COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS
This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing
C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
C07C 235/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
C07C 235/08 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
C07C 259/06 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
C07F 9/117 - Esters of phosphoric acids with cycloaliphatic alcohols
C07C 69/712 - Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
C07C 51/41 - Preparation of salts of carboxylic acids by conversion of the acids or their salts into salts with the same carboxylic acid part
A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/223 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-amino acids
61.
A DRY POWDER COMPOSITION OF TRESTINIL AND ITS PRODRUG THEREOF AND FURTHER COMPRISING COMPRISING (E)-3,6-BIS[4-(N-CARBONYL-2-PROPENYL)AMIDOBUTYL]-2,5-DIKETOPIPERAZINE (FDKP)
Provided are treprostinil derivatives with a reduced ability to form undesired impurities in a pharmaceutical formulation, such as a dry powder formulation, further containing a carboxyl group containing inactive ingredient, such as fumaryl diketopiperazine.
C07C 69/28 - Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/255 - Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
C07C 69/16 - Acetic acid esters of dihydroxylic compounds
C07C 69/96 - Esters of carbonic or haloformic acids
62.
A DRY POWDER COMPOSITION OF TRESTINIL AND ITS PRODRUG THEREOF AND FURTHER COMPRISING COMPRISING (E)-3,6-BIS[4-(N-CARBONYL-2-PROPENYL)AMIDOBUTYL]-2,5-DIKETOPIPERAZINE (FDKP)
Provided are treprostinil derivatives with a reduced ability to form undesired impurities in a pharmaceutical formulation, such as a dry powder formulation, further containing a carboxyl group containing inactive ingredient, such as fumaryl diketopiperazine.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Provided are treprostinil derivatives with a reduced ability to form undesired impurities in a pharmaceutical formulation, such as a dry powder formulation, further containing a carboxyl group containing inactive ingredient, such as fumaryl diketopiperazine.
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
A61K 9/00 - Medicinal preparations characterised by special physical form
Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
Provided are methods for treating or preventing myocarditis by administering extracellular vesicles, including exosomes. In some embodiments, the EVs are from bone marrow-derived mesenchymal stem (or stromal) cells. The myocarditis can be the result of viral infections such as Coxsackievirus B virus, SARS-CoV-2, or other viruses.
Provided are methods for treating or preventing myocarditis by administering extracellular vesicles, including exosomes. In some embodiments, the EVs are from bone marrow-derived mesenchymal stem (or stromal) cells. The myocarditis can be the result of viral infections such as Coxsackievirus B virus, SARS-CoV-2, or other viruses.
C07C 67/343 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisationPreparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by change of size of the carbon skeleton by increase in the number of carbon atoms
C07C 45/67 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by isomerisationPreparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by change of size of the carbon skeleton
C07C 45/81 - SeparationPurificationStabilisationUse of additives by change in the physical state, e.g. crystallisation
C07C 67/31 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
C07C 67/333 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisationPreparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by change of size of the carbon skeleton
C07C 45/64 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by introduction of functional groups containing oxygen only in singly bound form
C07C 45/78 - SeparationPurificationStabilisationUse of additives
68.
METHODS OF TREATING DISEASE WITH TREPROSTINIL PRODRUGS
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
Methods of treatment of pulmonary hypertension comprising dry powder inhalation administration of imatinib, a pharmaceutically acceptable salt, or a derivative thereof, are provided. Dry powder inhalable compositions comprising imatinib, a pharmaceutically acceptable salt, or a derivative thereof, are also provided as well as methods of making the same.
Methods of treatment of pulmonary hypertension comprising dry powder inhalation administration of imatinib, a pharmaceutically acceptable salt, or a derivative thereof, are provided. Dry powder inhalable compositions comprising imatinib, a pharmaceutically acceptable salt, or a derivative thereof, are also provided as well as methods of making the same.
Methods of treatment of pulmonary hypertension comprising dry powder inhalation administration of imatinib, a pharmaceutically acceptable salt, or a derivative thereof, are provided. Dry powder inhalable compositions comprising imatinib, a pharmaceutically acceptable salt, or a derivative thereof, are also provided as well as methods of making the same.
Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
Genetically-modified mesenchymal stem cells (MSCs) overexpressing an acyloxyacyl hydrolase (AOAH) polypeptide, such as MSCs comprising a recombinant nucleic acid encoding the AOAH polypeptide, are described. The MSCs may further overexpress a second polypeptide of interest, such as angiopoeitin-1 (ANGPT1). Pharmaceutical compositions comprising the genetically-modified MSCs are also described. The use of such genetically-modified MSCs and/or pharmaceutical compositions comprising same as a medicament, for example for the treatment of systemic inflammatory response syndrome (SIRS) or sepsis, is also described.
Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
C07D 241/08 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C07D 241/08 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07D 307/93 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
80.
STRUCTURAL FEATURES OF A VEHICLE HAVING UTILITY TO TRANSPORT HIGH VALUE THINGS
An assembly, by way of example, an aircraft, including an aircraft motor apparatus including at least one motor located within a protective structure, the protective structure having movable sub-structure components, wherein the portion of the aircraft motor apparatus is configured to move the movable sub-structure components to increase or decrease airflow through the protective structure.
Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.
Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.
Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.
Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same. A preferred polymer has a repeating unit of the following structure:
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 31/558 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
C07C 67/08 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
Provided are methods for isolating potent extracellular vesicle populations from mesenchymal stem cells. In particular, the present disclosure identified a protein profile specific for MSC-derived EV populations. Moreover, disclosed herein is the use of the isolated extracellular vesicles in treating a variety of diseases and conditions, including chronic or acute lung diseases such as pulmonary hypertension, ARDS and diseases and conditions characterized by vasculopathy, reduced angiogenesis, apoptosis, mitochondrial dysfunction, acute inflammation, fibrosis, or chronic inflammation.
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 11/00 - Drugs for disorders of the respiratory system
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Provided are methods for isolating potent extracellular vesicle populations from mesenchymal stem cells. In particular, the present disclosure identified a protein profile specific for MSC-derived EV populations. Moreover, disclosed herein is the use of the isolated extracellular vesicles in treating a variety of diseases and conditions, including chronic or acute lung diseases such as pulmonary hypertension, ARDS and diseases and conditions characterized by vasculopathy, reduced angiogenesis, apoptosis, mitochondrial dysfunction, acute inflammation, fibrosis, or chronic inflammation.
Provided are methods for isolating potent extracellular vesicle populations from mesenchymal stem cells. In particular, the present disclosure identified a protein profile specific for MSC-derived EV populations. Moreover, disclosed herein is the use of the isolated extracellular vesicles in treating a variety of diseases and conditions, including chronic or acute lung diseases such as pulmonary hypertension, ARDS and diseases and conditions characterized by vasculopathy, reduced angiogenesis, apoptosis, mitochondrial dysfunction, acute inflammation, fibrosis, or chronic inflammation.
Provided are methods for isolating potent extracellular vesicle or exosome populations from mesenchymal stromal cells, and the use of the isolated extracellular vesicles or exosomes in treating vasculopathy, including pulmonary hypertension, bronchopulmonary dysplasia, and disease and conditions associated with mitochondrial dysfunction.
Described herein are noninvasive electrical stimulation devices, systems and methods for stimulation of the Vagus nerve through its auricular branch to provide beneficial physiological responses in subjects, including alleviation, mitigation or elimination of symptoms of various disorders, including metabolic and inflammatory disorders.
The United States of America as Represented by the Secretary, Department of Health & Human Services (USA)
Inventor
Meh, David
Atolagbe, Timothy
Farquharson, G. Mark
Shaban, Samir
Koleck, Mary
Mitra, George
Abstract
Disclosed here includes a method for purifying a biologic composition, comprising diafiltering the biologic composition into a composition comprising phosphate buffered saline (PBS) to obtain a purified composition. The method disclosed here can be particularly useful for removing one or more impurities from the biologic composition, such as bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (Bis-tris).
C07K 1/34 - ExtractionSeparationPurification by filtration, ultrafiltration or reverse osmosis
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
B01D 15/12 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the preparation of the feed
B01D 15/18 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
B01D 15/24 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the treatment of the fractions to be distributed
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
This invention provides a prefilled selectively activatable body-worn infusion-pump assembly for rapid delivery of large volumes or highly viscous volume comprising a housing; a pre-filled aseptically-sealed flexible drug reservoir-containing assembly; a conjoined, coordinately controlled and perpendicularly arranged cannulated needle dispensing and needle insertion assembly operationally connected to and in fluid connection with the pre-filled aseptically-sealed drug reservoir-containing assembly, wherein the cannulated needle dispensing assembly projects generally perpendicularly to a generally planar surface of the housing, promotes insertion of the cannulated needle in skin of a subject and promotes retraction of the needle within the cannulated needle dispensing assembly thereafter, and wherein the needle insertion assembly projects generally in a parallel orientation to a generally planar surface of the housing, which projection initiates opening a fluid path with the pre-filled aseptically-sealed drug reservoir-containing assembly; an engine assembly contained in the housing operationally connected to the pre-filled aseptically-sealed flexible drug reservoir-containing assembly promoting release of a drug contained therein, wherein the engine assembly comprises: a motor; a worm gear, operationally connected to the motor; a lifting gear, operationally connected to the worm gear; a piston operationally connected to the lifting gear; and a chassis fitted with an attachment promoting a floating connection thereto with the worm gear; wherein the worm gear and motor are mounted radially with respect to the chassis; a printed circuit board (PCB) assembly, which mechanically supports, electrically connects and controls the function of at least the engine assembly; and a single step activator that when engaged simultaneously promotes activation of the needle insertion assembly opening a fluid path with the pre-filled aseptically-sealed drug reservoir-containing assembly; activation of the engine assembly; and activation of the cannulated needle dispensing assembly inserting in a skin of a subject.
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/265 - Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
95.
METHODS AND COMPOSITIONS FOR CULTURING ALVEOLAR CELLS
Described herein are methods and compositions for use in expanding alveolar epithelial cells. The methods may include the use of three-dimensional substrates and improved techniques for expansion of the cells. The improved composition for culturing alveolar epithelial cells may include at least one or more of the following: a TGF-ß pathway inhibitor; a Wnt pathway activator; a ROCK inhibitor; an epidermal growth factor (EGF); a keratinocyte growth factor (KGF); and a fetal bovine serum.
Described herein are methods and compositions for use in expanding alveolar epithelial cells. The methods may include the use of three-dimensional substrates and improved techniques for expansion of the cells. The improved composition for culturing alveolar epithelial cells may include at least one or more of the following: a TGF-β pathway inhibitor; a Wnt pathway activator; a ROCK inhibitor; an epidermal growth factor (EGF); a keratinocyte growth factor (KGF); and a fetal bovine serum.
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 11/00 - Drugs for disorders of the respiratory system
C07C 405/00 - Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 295/088 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C07D 295/185 - Radicals derived from carboxylic acids from aliphatic carboxylic acids
A61K 31/265 - Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
C07C 69/612 - Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
C07C 69/616 - Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety polycyclic
C07C 69/767 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring esterified with unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
C07C 233/05 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 211/58 - Nitrogen atoms attached in position 4
C07D 295/088 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C07D 295/185 - Radicals derived from carboxylic acids from aliphatic carboxylic acids
Described herein are methods and compositions for use in expanding alveolar epithelial cells. The methods may include the use of three-dimensional substrates and improved techniques for expansion of the cells. The improved composition for culturing alveolar epithelial cells may include at least one or more of the following: a TGF-ß pathway inhibitor; a Wnt pathway activator; a ROCK inhibitor; an epidermal growth factor (EGF); a keratinocyte growth factor (KGF); and a fetal bovine serum.
A method for treating inflammatory diseases is provided. The method may include administering to a subject in need thereof a therapeutically effective amount of isolated extracellular vesicles or exosomes obtained from mesenchymal stem cells pre-conditioned with at least TNF-α. The isolated extracellular vesicles or exosomes may exhibit (a) enhanced expression of flotillin-1, (b) enhanced expression of CD73, or (c) enhanced expression of IDO. A method of isolating extracellular vesicles or exosomes capable of treating an inflammatory disease is also provided, wherein the method may include (a) culturing stem cells in a growth medium, (b) then culturing the stem cells in a starve medium supplemented with at least TNF-α, and (c) separating exosomes or extracellular vesicles from the culture. Cultures suitable for treatment are also provided.
